Publication

A review of bispecific antibodies and antibody constructs in oncology and clinical challenges

Suurs, F. V., Lub-de Hooge, M. N., de Vries, E. G. E. & de Groot, D. J. A., Sep-2019, In : Pharmacology & Therapeutics. 201, p. 103-119 17 p.

Research output: Contribution to journalReview articleAcademicpeer-review

Bispecific antibodies (bsAbs) are antibodies that bind two distinct epitopes to cancer.. For use in oncology, one bsAb has been approved and 57 bsAbs are in clinical trials, none of which has reached phase 3. These bsAbs show great variability in design and mechanism of action. The various designs are often linked to the mechanisms of actions. The majority of bsAbs engage immune cells to destroy tumor cells. However, some bsAbs are also used to deliver payloads to tumors or to block tumor signaling pathways. This review provides insight into the choice of construct for bsAbs, summarizes the clinical development of bsAbs in oncology and identifies subsequent challenges. (C) 2019 The Authors. Published by Elsevier Inc.

Original languageEnglish
Pages (from-to)103-119
Number of pages17
JournalPharmacology & Therapeutics
Volume201
Early online date24-Apr-2019
Publication statusPublished - Sep-2019

    Keywords

  • Bispecific antibody (bsAb), Antibody constructs, Oncology, Cancer immunotherapy, Clinical trials, SINGLE-CHAIN ANTIBODY, MEDULLARY-THYROID CARCINOMA, T-CELLS, MONOCLONAL-ANTIBODIES, BITE ANTIBODY, PHASE-I, PRETARGETED RADIOIMMUNOTHERAPY, ANTITUMOR-ACTIVITY, TARGETED DELIVERY, ANTIGEN-BINDING

View graph of relations

ID: 92268823